A bionic pancreas designed to take over blood sugar control in people with type 1 diabetes got patients to near normal levels and prevented dangerous drops better than standard therapy in two demanding five-day trials.
Diet and exercise remain the best bet for staving off diabetes in patients at risk for the disease, according to a 15-year follow up on a landmark study that set lifestyle intervention as an effective approach.
Sanofi’s experimental insulin Toujeo controlled diabetes better than the company’s best-selling Lantus in three tests that suggest the new drug may help buoy sales when the older one loses patent protection.
Patients taking Eli Lilly & Co.’s experimental diabetes drug dulaglutide lost weight and had side effects that were manageable, the company said today after releasing more data from three final-stage clinical trials.
Aug. 30 (Bloomberg) -- An InfoCision representative calls a prospective volunteer to ask them to participate in a mailing campaign to solicit funds for the American Diabetes Association. (Source: Bloomberg)
Sanofi’s experimental diabetes drug U300 helped control glucose with fewer patients experiencing incidents of dangerously low blood-sugar levels at night than the company’s Lantus in two clinical trials.